Apotex Inc — licence 100375, currently licensed, last inspection rating C (2026-04-21).
No Canadian shortage report is currently matched to this DIN.
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02562502 | APO-DASATINIB TABLETS | APOTEX INC | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 100 MG | Marketed |
| 02562499 | APO-DASATINIB TABLETS | APOTEX INC | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 80 MG | Marketed |
| 02562480 | APO-DASATINIB TABLETS | APOTEX INC | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 70 MG | Marketed |
| 02562472 | APO-DASATINIB TABLETS | APOTEX INC | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 50 MG | Marketed |
| 02360810 | SPRYCEL | BRISTOL-MYERS SQUIBB CANADA | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 80 MG | Marketed |
| 02360829 | SPRYCEL | BRISTOL-MYERS SQUIBB CANADA | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 140 MG | Marketed |
| 02293129 | SPRYCEL | BRISTOL-MYERS SQUIBB CANADA | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 20 MG | Marketed |
| 02293137 | SPRYCEL | BRISTOL-MYERS SQUIBB CANADA | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 50 MG | Marketed |
| 02293145 | SPRYCEL | BRISTOL-MYERS SQUIBB CANADA | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 70 MG | Marketed |
| 02320193 | SPRYCEL | BRISTOL-MYERS SQUIBB CANADA | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 100 MG | Marketed |
| 02478358 | TEVA-DASATINIB | TEVA CANADA LIMITED | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 100 MG | Marketed |
| 02478331 | TEVA-DASATINIB | TEVA CANADA LIMITED | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 80 MG | Marketed |
| 02478323 | TEVA-DASATINIB | TEVA CANADA LIMITED | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 70 MG | Marketed |
| 02478315 | TEVA-DASATINIB | TEVA CANADA LIMITED | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 50 MG | Marketed |
| 02478307 | TEVA-DASATINIB | TEVA CANADA LIMITED | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 20 MG | Marketed |